Case-Based Overview: NTRK Fusion–Positive mCRC

Testing for NTRK Fusion–Positive Metastatic Colon Cancer

Treatment Options for NTRK Fusion–Positive mCRC

NTRK-Targeted Therapy for Patients With Colon Cancer

NTRK-Targeted Therapy in Colon Cancer: Dosing and Management

NTRK Fusion–Positive Colon Cancer: Final Thoughts

Case: A 68-Year-Old Woman With Metastatic 

A 68-year-old woman presented with a 3-month history of intermittent abdominal pain, and alternating constipation/diarrhea

PMH/SH: hypertension and hypercholesterolemia, medically managed; colonoscopy at age 50 was unremarkable; never smoker; no family history of cancer

PE: abdomen tender on deep palpation in the right lower quadrant

Labs: Hb 11.9, Hct 32%, MCV 75 fL, CEA 12.8 ng/mL

Chest/abdominal/pelvic CT showed a 5-cm right sided bowl mass and multiple hepatic lesions, and regional lymphadenopathy

Colonoscopy revealed a 5-cm mass in the ascending colon, biopsy was taken

Pathology: grade 3 poorly differentiated adenocarcinoma, with invasion of the submucosa

Biomarkers: KRAS-wt, NRAS-wt, BRAF-, NTRK+; MSI-H

Case Based Peer Perspectives

Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.